首页> 外文期刊>HNO >Prophylaxis of venous thromboembolism and anticoagulation bridging : Strategies in otorhinolaryngology
【24h】

Prophylaxis of venous thromboembolism and anticoagulation bridging : Strategies in otorhinolaryngology

机译:预防静脉血栓栓塞和抗凝桥接:耳鼻咽喉科的策略

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Various interdisciplinary guidelines recommend that in-patients at risk of venous thromboembolism should receive pharmacologic prophylaxis. Among the anticoagulants low-molecular-weight heparins (LMWH) and fondaparinux can be considered the medications of choice because of the favorable pharmacokinetic properties when compared with unfractionated heparin. Treatment with vitamin K antagonists has to be interrupted in patients undergoing major surgery or invasive procedures. Oral anticoagulation has to be temporarily replaced by short-acting anticoagulants such as LMWH in order to prevent thromboembolic complications (anticoagulation bridging). Although LMWHs have not been approved for this clinical setting their efficacy and safety has been demonstrated in several recent studies. Detailed recommendations for prophylaxis of venous thromboembolism in otorhinolaryngology are lacking although numerous surgical procedures are considered to be associated with a significant risk of thromboembolism. A strategy for pharmacologic prophylaxis of venous thromboembolism and anticoagulation bridging in otorhinolaryngology is proposed.
机译:各种跨学科指南均建议有静脉血栓栓塞风险的住院患者应接受药物预防。在抗凝剂中,由于低分子量肝素(LMWH)和磺达肝癸钠与普通肝素相比具有良好的药代动力学特性,因此可以视为首选药物。在进行大手术或侵入性手术的患者中,必须中断使用维生素K拮抗剂的治疗。口服抗凝药必须暂时用短效抗凝药如LMWH代替,以防止血栓栓塞并发症(抗凝桥接)。尽管尚未批准LMWH用于该临床研究,但最近的一些研究已经证明了它们的功效和安全性。尽管许多外科手术被认为与血栓栓塞的显着风险有关,但在耳鼻咽喉科中尚缺乏预防静脉血栓栓塞的详细建议。提出了一种在耳鼻喉科中预防静脉血栓栓塞和抗凝桥接的药理策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号